Articles tagged with Immunotherapy
Researchers have found a new potential therapeutic target for autoimmune diseases such as lupus and multiple sclerosis by identifying an overlooked sequence in the IκBζ protein. This sequence, known as the OCA peptide, can activate key proteins in immune cells and may help reeling in immune cells gone haywire.
Researchers found that widely used machine learning tools produce biased results for immunotherapy research, as they rely heavily on datasets from higher-income communities. This can lead to ineffective treatments for lower-income populations. The study highlights the need for accurate and unbiased data in machine learning models.
A new study has identified a genetic marker that can predict which patients are likely to respond to immunotherapy in various types of cancer. Tumors with high intragenic rearrangement (IGR) burden, which indicates cryptic structural rearrangements of the genetic code, may respond better to immunotherapy.
A new clinical trial demonstrates a small reduction in the latent reservoir of HIV-infected cells using a combination of vorinostat and immunotherapy. While the results are promising, further research is needed to create more effective approaches to flush out the virus and attack it when it emerges from latency.
Researchers discovered that VISTA induces immune suppressor cells called myeloid-derived suppressor cells (MDSCs) through a feedback loop involving STAT3 and polyamines. This pathway has high translational impact for several human cancers, offering promising drug targets.
A systematic review found that female individuals and caregivers tend to report a greater impact of food allergy on health-related quality of life. Additionally, males may experience more improvements in quality of life following immunotherapy for food allergy.
Researchers found that tumors with preexisting immune cell networks were most primed to respond to adoptive T cell therapy, and patients whose tumors featured such networks responded best to treatment. The study provides a step towards identifying patients who are likely to benefit from personalized immunotherapies.
Senescent tumour cells generated by chemotherapy can create an environment that helps tumour cells escape treatment. Eliminating these cells with immunotherapy boosts the effectiveness of chemotherapy.
Researchers have discovered that CAR T cells can be repurposed to target senescent cells, which accumulate with age and cause inflammation. This breakthrough offers a promising alternative to existing treatments, which often require repeated administration.
Researchers have revealed CD4+ T cells can work effectively on their own to control melanoma, challenging conventional understanding. Harnessing their potential therapeutically holds great promise for improving current cancer immunotherapies.
Researchers found that specific microbes in the gut reduce graft versus host disease after stem cell transplantation. Patients with low microbial metabolite risk index had better survival rates, fewer graft vs. host reactions, and reduced relapses.
Researchers uncover a link between hyperactive Rac2 and human immune deficiency, shedding light on a mysterious condition. They also find promise in using cellular cannibalism to enhance cancer treatment.
A Stanford University study reveals that ENPP1 is produced by both cancer cells and healthy cells around tumors, with high levels linked to immunotherapy resistance and metastases. Researchers found that targeting ENPP1 could improve patient responses to existing medicines and help clinicians better predict patient outcomes
A phase 1 clinical trial demonstrates the efficacy of third-generation anti-CD19 CAR T-cells in treating relapsed or refractory B-cell non-Hodgkin lymphomas without causing neurotoxicity. The study also shows a robust response rate of 52% and improved safety profile compared to previous CAR T-cell therapies.
A world-first human trial shows that a commonly prescribed rheumatoid arthritis drug can safely and effectively preserve the body's own insulin production and suppress the progression of type 1 diabetes. The drug, baricitinib, was found to be effective in maintaining insulin production in people who initiated treatment within 100 days ...
Researchers discovered distinct mechanisms controlling different types of immune cells and found a way to selectively eliminate 'problematic' cells driving autoimmune disorders. This breakthrough offers precise targets for potential treatment strategies, potentially revolutionizing the way we treat skin conditions.
Researchers are exploring new ways to fight metastasis, including the use of bacteria to activate a defensive response against cancer. Stress and changes in circadian rhythms have also been linked to metastasis, suggesting that these factors may be targets for prevention or treatment.
Researchers have successfully used a specially formulated toothpaste for Oral Mucosal Immunotherapy (OMIT) to desensitize adults with peanut allergies. The study showed that 100% of participants consistently tolerated the highest dose without severe reactions, and 97% adhered to treatment.
Maintenance immunosuppressive drugs linked to increased COVID-19 hospitalization risk in solid organ transplant patients. Clinicians treating transplant recipients should consider these findings for epidemic-related decisions.
Researchers found that beta-blockers can revive exhausted killer T cells, making them better cancer fighters. The study discovered a link between the sympathetic stress response and immune system response to cancer.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
A recent study found that ChatGPT scored 9/10 in accuracy for debunking Covid-19 vaccine myths, making it a reliable source of non-technical information. The AI tool's responses were accurate in addressing both true and false contraindications, but highlighted potential concerns over changes in answers over time.
Researchers at Gladstone Institutes identified conditions that enable gamma delta T cells to recognize cancer cells by disrupting energy production and causing cellular stress. This insight suggests that therapies manipulating butyrophilin abundance on the surface of cancer cells could boost gamma delta T cell effectiveness.
A recent case study highlights the challenges faced by families seeking venom immunotherapy for fire ant allergies, particularly in low-income communities. Despite proven safety and effectiveness of treatment, access remains a significant issue due to transportation barriers, lack of childcare, and work constraints.
A new study published in BMJ Oncology has found that relatively short-term use of immunosuppressant medications to control inflammatory diseases is not associated with an increased risk of developing cancer. The research included over 10,000 participants and tracked their cancer incidence for an average of 10 years.
Researchers have developed an oncolytic virus that can 'warm up' cold tumors and improve immunotherapy outcomes. The virus was engineered to carry a gene encoding a TGF-β inhibitor, which greatly increased survival rates in mice with aggressive melanoma and other cancers.
Researchers found that ranolazine, a heart medication, slows down tumor progression and increases visibility of melanoma cells to the immune system. This combination could improve response rates for immunotherapies in patients with melanoma.
Research suggests gut microbiota plays a crucial role in shaping immunotherapy response, with alterations contributing to cancer progression. The study aims to discuss the effect of microbiota on cancer immunotherapy and potential applications for improving treatment outcomes.
Researchers discovered that STING, a critical immune regulator, can act as an ion channel to control immune responses. This new function allows STING to translate danger signals into ion flow, activating various defense mechanisms.
The IBS-KAI Conference will focus on viral diseases and immunology, featuring over 20 international experts. The conference aims to prepare for responses to future infectious diseases, including those with pandemic potentials.
A study published in Cancers found that a combination of radiotherapy followed by immunotherapy is effective against oral malignant melanomas in dogs. The treatment strategy increased overall survival time compared to immunotherapy alone. Researchers are now exploring the optimal protocol for this therapy to increase its effectiveness.
Researchers discuss the potential of glucocorticoid-induced TNFR-related protein (GITR) as a target for cancer immunotherapy. Preclinical studies have shown potent anti-tumor efficacy, but clinical trials have yielded inconsistent results due to complexities in immune responses and antibody structure.
Researchers have identified a key protein in the body's innate ability to fight systemic fungal infections. The study found that C5a and its downstream effects are crucial for immune cells to clear the fungus Candida albicans when it overtakes natural defenses.
A new study found that food allergy affects all racial and ethnic groups, but is most prevalent among Hispanic, non-Hispanic Black, and Asian individuals. Food allergy rates are also lower in households with higher incomes.
A study of 17,000 people across eight African countries found a decline in vaccine confidence, particularly for COVID-19 vaccines. The drop in routine childhood vaccinations has led to six million fewer children receiving life-saving shots, putting decades of progress at risk.
The Phase 3 S1826 trial demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma treated with nivolumab and chemotherapy. The therapy was well-tolerated, with few serious immune-related side effects.
A new CAR T cell design approach using machine learning and artificial intelligence is being developed to improve cancer treatment. The project aims to create a hybrid knowledge- and data-driven approach to guide the design of immunotherapeutic cells.
A year-long immunotherapy through a skin patch safely desensitized toddlers with peanut allergy, lowering the risk of a severe allergic reaction from accidental exposure. Children who originally reacted to small amounts of peanuts were able to tolerate larger quantities after completing treatment.
Researchers from Rice University and Baylor College of Medicine are developing a new 'glyco-immune' checkpoint inhibitor to train the immune system to target and kill breast cancer metastasis in bones. The therapy has shown promise in preliminary tests, including eradicating cancer in some animals.
A recent study published in the Journal of Clinical Immunology suggests that cutaquig infusions at higher infusion rates and volumes are well-tolerated and effective, with reduced infusion time, fewer injection sites, and improved compliance. The study results will be presented at the Clinical Immunology Society 2023 Annual Meeting.
University of Pittsburgh researchers created a universal receptor system allowing T cells to recognize any cell surface target. This enables highly customizable CAR T cell and other immunotherapies for treating cancer and diseases, with potential applications in solid tumors.
Blinatumomab immunotherapy significantly improves the survival rate of babies with aggressive acute lymphoblastic leukemia (ALL), from 66% to 93%, while reducing side effects. The treatment is now standard for babies worldwide.
Tumors with low PD-L1 levels use genetic strategies like MYC activation to avoid immune attack, but this can be predicted by monitoring for MYC status. The study's findings could lead to new clinical trials assessing MYC status as a marker for selecting patients for immunotherapy.
Researchers found that probiotic bacteria Lactobacillus reuteri stimulates cancer-killing T cells by secreting indole-3-aldehyde, which activates a receptor in CD8 cells. A diet rich in tryptophan enhances the effect of immunotherapy on shrinking tumors and prolonging survival.
An international panel of experts has developed standardized definitions for immunotherapy side effects, providing a shared vocabulary for clinicians to standardize clinical practice guidelines. This will help support clinicians in offering the best treatment to patients and enable research into biomarkers predicting adverse effects.
Elizabeth M. Jaffee, MD, FAACR, is being recognized for her exceptional leadership, scientific discoveries, and contributions to cancer immunotherapy. Her research has significantly broadened understanding of the interaction between the immune system and pancreatic cancer.
Researchers found a strong association between high levels of telomerase reverse transcriptase (TERT) expression and an elevated immune response in patients with head and neck squamous cell carcinoma. This link suggests a potential new target for cancer immunotherapies, which may lead to improved outcomes for patients.
A new study has identified the steps by which immune cells recognize and respond to cancer cell mutations, providing insights into why some treatments work for certain patients but not others. Researchers believe their findings will lead to better, more personalized immunotherapies for patients whose immune systems currently do not app...
Researchers discovered that quiescent ovarian cancer cells secrete follistatin, which induces resistance in neighboring cells and worsens survival rates. Targeting this protein may improve chemotherapy response and boost survival in patients with aggressive ovarian cancer.
Aleksandar Obradovic's work harnesses anti-tumor immune response with tailored cancer immunotherapy, combining drug treatments and immune-response therapeutics. He developed algorithms to predict drug sensitivity and identify groups of cells associated with treatment resistance.
Dr. Carl H. June is recognized for his pioneering work in developing gene-edited cell therapy for cancer and demonstrating its potential to induce remission and cure patients with advanced cancer. His technology has led to the FDA approval of six CAR T-cell therapies for multiple blood cancers.
Researchers at Rice University have developed light-activated nanoscale drills that can kill pathogenic fungi, providing a potential new treatment option for fungal infections. The molecular machines target the mitochondria of fungal cells, disrupting cellular metabolism and leading to cell death.
Researchers developed a translational step forward in treating brain tumors using intraventricular immunovirotherapy, which has shown safety and efficacy in recent clinical trials. This approach uses oncolytic herpes simplex virus type-1 to target high-grade glioma with promising results.
A clinical trial found that boiling peanuts for up to 12 hours can desensitize children with peanut allergies. The therapy involved sequential doses of boiled and roasted peanuts, achieving high success rates in participants. While promising, the study's findings require confirmation in larger trials.
A phase 2 clinical trial using boiled peanuts followed by roasted peanuts showed promising results in desensitizing 80% of children with peanut allergies. Treatment-related adverse events were reported in 61% participants.
Extracellular vesicles from immune cells have been shown to activate the immune system in mice with skin cancer, rendering them sensitive to checkpoint inhibitor therapy. The treatment improved survival rates when used in combination with checkpoint inhibitors.
The E1910 trial found that adding blinatumomab to standard front-line consolidation chemotherapy improved overall survival and kept most patients in remission. The treatment, which targets malignant B cells, demonstrated its effectiveness in patients with a good prognosis after an initial round of chemotherapy.
Researchers have developed a CAR-T therapy approach that effectively targets and eliminates rogue immune cells responsible for autoimmune diseases like multiple sclerosis. The treatment shows promise as a potential cure for debilitating conditions.
The German Research Foundation has approved a new Collaborative Research Center at the University Medical Center Mainz, exploring regulatory T cells in immune-related and tissue-specific diseases. The project aims to develop tailored immunotherapies using Treg cells, which could lead to breakthroughs in patient care.
Johannes Gutenberg University Mainz has been awarded funding for three Collaborative Research Centers in the life sciences, including CRC 1551 and CRC/Transregio 355. The centers will focus on investigating polymer concepts in cellular function and heterogeneity of regulatory T cells in distinct microenvironments.